Condition
Metastatic Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownEfficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint BlockadeNCT07130032 · 2025-08-14
RECRUITINGClinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma PatientsNCT02622581 · 2015-12-01
RECRUITINGA Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerNCT04466917 · 2021-05-15
WITHDRAWNUCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC PatientsNCT03158883 · 2017-05-17
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
RECRUITING2
COMPLETED1
WITHDRAWN1
Phase mix
EARLY_PHASE11
PHASE21
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.